Celcuity (CELC) Other Non-Current Assets (2017 - 2025)
Celcuity (CELC) reported Other Non-Current Assets of $349000.0 for Q4 2025, up 598.0% quarter-over-quarter from $50000.0 in Q2 2018.
Celcuity (CELC) Other Non-Current Assets (2017 - 2025) Analysis & Trends
Celcuity has reported Other Non-Current Assets for 3 years, with the latest figure at $349000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets changed N/A year-over-year to $349000.0; the trailing twelve-month figure through Dec 2025 stood at $349000.0 (changed N/A YoY), and the FY2025 full-year result was $349000.0, changed N/A from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $349000.0, up from $50000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $349000.0 in Q4 2025, with the low at $349000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | 349,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 349,000.00 |
| Jun 30, 2018 | 50,000.00 |
| Mar 31, 2018 | 50,000.00 |
| Dec 31, 2017 | 50,000.00 |
| Sep 30, 2017 | 50,000.00 |
| Jun 30, 2017 | 50,000.00 |
| Mar 31, 2017 | 50,000.00 |